PVIVAX

Map with highlighted countries to indicate where studies are taking place

P. vivax malaria studies: A database of studies focusing on improving access to radical cure.

View the database

About the P. vivax information hub.

Find out more

Photo: istock

Featured resources

The Partnership for Vivax Elimination (PAVE)

The Partnership for Vivax Elimination (PAVE) supports countries in adopting new and existing tools and approaches to achieve universal access to the best clinical practices for P. vivax case management.

05 Aug 2021

New treatment for P. vivax malaria may benefit Brazilian public health

This briefing provides an overview of the population-level transmission dynamics modelling study by Nekkab et al. on the estimated impact of tafenoquine (TQ) on control and elimination of P. vivax malaria in Brazil. The briefing is available in English, Spanish and Portuguese.

Partnership for Vivax Elimination (PAVE)

Fact sheet

Healthworker and patient in a consultation

Partnership for Vivax Elimination (PAVE) Feasibility Studies and Operational Research

PAVE is conducting feasibility studies and operational research to support Ministries of Health in malaria endemic countries to look at the best way to use different P. vivax relapse treatments and diagnostics at different levels of the healthcare system in support of their elimination goals.

Patient and health worker in consultation

the Tafenoquine Roll-oUt STudy (TRuST)

The Brazilian Ministry of Health (MoH) and MMV, are conducting a study to understand the feasibility of providing appropriate radical cure treatment (primaquine - PQ - or tafenoquine – TQ) based on the results of G6PD testing conducted in real-world settings.

News

children sitting under a mosquito bed net.

Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration

14 Mar 2022

P. vivax radical cure in Latin America: regional coordination to advance malaria elimination

17 Dec 2021

microbiology laboratory in Porto Velho, Brazil

First real-world use of new protocol for P. vivax case management in Brazil – a Health Ministry and MMV collaboration

08 Oct 2021

New Partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide

14 Jul 2021

View news and events

Events

Publications

22 Feb 2022

Community engagement for malaria elimination in the Greater Mekong Sub-region: a qualitative study among malaria researchers and policymakers

This article explores the perspectives of researchers and policy makers in the Greater Mekong Sub-region (GMS) on community engagement for malaria control and elimination.

Malaria Journal

Peer-reviewed article

Available online 3 December 2021

Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

Single-dose tafenoquine 300 mg is approved for Plasmodium vivax malaria relapse prevention in patients at least 16 years old. We aimed to determine appropriate oral tafenoquine paediatric dosing regimens, including a dispersible formulation, and evaluated tafenoquine efficacy and safety in children infected with P. vivax.

Lancet Child & Adolescent Health

Peer-reviewed article

30 Oct 2021

Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria

This study aimed to map out the national antimalarial policy processes in seven endemic countries to identify areas where it can be improved to align with best practices and optimal efficiency.

Malaria Journal

Peer-reviewed article

08 Oct 2021

Eliminating malaria in southeast Asia requires more attention on adolescent girls

Malaria is one of the leading causes of death among adolescent girls in southeast Asia. Young adolescent girls (aged 10–14 years), for whom malaria is the eighth highest cause of mortality, are most affected. On the basis of the most recent data (which is for the year 2016), the malaria mortality rate for young adolescent girls in southeast Asia is 28% higher than for young adolescent boys (1·75 deaths vs 1·37 deaths [per 100 000 of the population at risk]).

Lancet Child Adolescent Health

Peer-reviewed article

View all publications

Knowledge sharing for relapsing malaria

Search

Featured resources

The Partnership for Vivax Elimination (PAVE)

New treatment for P. vivax malaria may benefit Brazilian public health

Partnership for Vivax Elimination (PAVE) Feasibility Studies and Operational Research

the Tafenoquine Roll-oUt STudy (TRuST)

News

Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration

P. vivax radical cure in Latin America: regional coordination to advance malaria elimination

First real-world use of new protocol for P. vivax case management in Brazil – a Health Ministry and MMV collaboration

New Partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide

Events

Publications

Community engagement for malaria elimination in the Greater Mekong Sub-region: a qualitative study among malaria researchers and policymakers

Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria

Eliminating malaria in southeast Asia requires more attention on adolescent girls

Get in touch

Subscribe

Follow us